Circulating Omentin as a Novel Biomarker for Colorectal Cancer Risk: Data from the EPIC-Potsdam Cohort Study
Circulating Omentin as a Novel Biomarker for Colorectal Cancer Risk: Data from the EPIC-Potsdam Cohort Study
复制标题
DOI：
10.1158/0008-5472.can-15-3464
复制
发表时间：
2016-07-01
期刊：
影响因子：
11.2
通讯作者：
Boeing, Heiner
中科院分区：
文献类型：
--
作者：
Aleksandrova, Krasimira;di Giuseppe, Romina;Boeing, Heiner
Omentin是一种新型生物标志物，具有代谢、炎症和免疫相关特性，因此可能与结直肠癌的风险有关。到目前为止，还没有前瞻性队列研究评估大网膜与结直肠癌风险之间的关系。在欧洲癌症与营养前瞻性调查波茨坦研究中，我们研究了诊断前血浆大网膜蛋白浓度与结直肠癌风险之间的关系，该研究包括251例结直肠癌病例，平均随访时间为10.4年，2295名未患癌症的人。风险比作为相对风险（RR）和95%置信区间（CI）的度量，使用Prentice-modified Cox回归计算。在校正了年龄、性别、教育程度、饮食和生活方式因素、体重指数（BMI）和腰围的多变量模型中，高网膜浓度与较高的结直肠癌风险相关(rr连续（每网膜浓度加倍）= 1.98；95% ci, 1.45-2.73)。额外调整代谢生物标志物，包括糖化血红蛋白、高密度脂蛋白胆固醇和c反应蛋白，没有改变结果。在分层分析中，在BMI = 30的参与者中，大网膜蛋白与结直肠癌风险之间保持正相关，但未发现相关（大网膜蛋白浓度每增加一倍的rrcontinuous = 1.07; 95% CI, 0.63-1.83； p -交互作用= 0.005）。这些新发现为诊断前大网膜浓度与结直肠癌风险之间的独立关联提供了第一手证据，并提示与个体的肥胖状态可能存在相互作用。(c) 2016年aacr。
Omentin is a novel biomarker shown to exert metabolic, inflammatory, and immune-related properties and thereby could be implicated in the risk of colorectal cancer. So far, the association between omentin and colorectal cancer risk has not been evaluated in prospective cohort studies. We investigated the association between prediagnostic plasma omentin concentrations and risk of colorectal cancer in a case-cohort comprising 251 incident colorectal cancer cases diagnosed over a mean follow-up time of 10.4 years and 2,295 persons who remained free of cancer in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. Hazard ratios as a measure of relative risk (RR) and 95% confidence intervals (CI) were computed using a Prentice-modified Cox regression. In a multivariable model adjusted for age, sex, education, dietary and lifestyle factors, body mass index (BMI), and waist circumference, higher omentin concentrations were associated with a higher colorectal cancer risk (RRcontinuously (per doubling of omentin concentrations) = 1.98; 95% CI, 1.45-2.73). Additional adjustment for metabolic biomarkers, including glycated hemoglobin, high-density lipoprotein cholesterol, and C-reactive protein, did not alter the results. In stratified analyses, the positive association between omentin and colorectal cancer risk was retained in participants with BMI = 30 no association was revealed (RRcontinuously per doubling of omentin concentrations = 1.07; 95% CI, 0.63-1.83; P-interaction = 0.005). These novel findings provide the first lines of evidence for an independent association between prediagnostic omentin concentrations and colorectal cancer risk and suggest a potential interaction with the adiposity state of the individual. (C) 2016 AACR.